Skip to content
Medical Health Aged Care

New research: People with dementia less likely to be referred to allied health services by GPs

Monash University 2 mins read

Researchers from Monash University’s Rehabilitation, Ageing and Independent Living (RAIL) Research Centre and the National Centre for Healthy Ageing (a partnership between Monash University and Peninsula Health) found that people with dementia were significantly less likely to receive any allied health referral compared with those with stroke or Parkinson’s disease.

 

Led by Dr Angel Lee, from the School of Primary and Allied Health Care and published in the BMJ Journal Family Medicine and Community Health, the research examined the allied health referral patterns of general practitioners from 537 practices for people with dementia compared to those without dementia across two large Primary Health Networks (PHNs) in Melbourne. Just under 700,000 patients were identified in the study, including 16,610 patients with dementia. 

 

Dr Lee said that GPs play an important role in informing patients about allied health services and coordinating referrals to facilitate access in Australia. Yet until now, the GP referral patterns had remained poorly understood and under-investigated.

 

“Despite strong evidence supporting allied health interventions for dementia, referral rates remain comparatively low. Accessing these services can provide therapeutic and diagnostic support for people living with dementia, with a focus on enhancing function, autonomy and quality of life,” Dr Lee said.

 

“Access to allied health could be improved through greater community awareness, integrated dementia-specific care pathways, implementing supportive policy changes and upskilling health professionals in the role of allied health in dementia care."

 

Co-author Professor Michele Callisaya, from the National Centre for Healthy Ageing and the University of Tasmania, aimed to address this by co-designing solutions to reduce stigma and to improve knowledge about the role of allied health in dementia care, both broadly within the community, and specifically for health professionals. 

 

Professor Callisaya worked alongside researchers and partners to implement and evaluate the solutions, creating educational resources, including a brochure and online training about the role of allied health in dementia care. 

 

“Allied health professionals have an important role in working with people with dementia and care partners, by supporting them to maximise participation in activities and roles that are meaningful and important to them. However, there are few allied health professionals working in this area,” Professor Callisaya said. 

 

“To improve referrals and access to allied health we need to train more allied health professionals to work in this growing area, and make sure those with expertise are easy to find.”

 

MEDIA ENQUIRIES 

Helena Powell

Media Advisor (medical), Monash University 

M: +61 474 444 171

E: [email protected] 

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: [email protected]

For more Monash media stories, visit our news and events site 

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.